CLEC9A, Recombinant, Human (C-type Lectin Domain Family 9 Member A, UNQ9341/PRO34046)
Catalog No : USB-C5839-73K
705.77€
0.00€
Shipping cost plus VAT not included , delivery in 7-14 business days
| Product name | CLEC9A, Recombinant, Human (C-type Lectin Domain Family 9 Member A, UNQ9341/PRO34046) | ||
|---|---|---|---|
| Catalog No | USB-C5839-73K | ||
| Supplier’s Catalog No | C5839-73K | ||
| Supplier | US Biologicals | ||
| Source antigen | Recombinant, NS0-derived, murine myeloma cell line | ||
| Reactivity | |||
| Cross reactivity | |||
| Applications | |||
| Molecular weight | 47 | ||
| Storage | -20°C | ||
|---|---|---|---|
| Other names | |||
| Grade | Highly Purified | ||
| Purity | ~95% (SDS-PAGE, reducing conditions) | ||
| Form | Supplied as a lyophilized powder from PBS. Reconstitute with 250ul sterile PBS. | ||
| Reactivity life | 12 months | ||
| Note | For reserch purpose only | ||
| Purity | ~95% (SDS-PAGE, reducing conditions) | ||
| Description | CLEC9a (C-type lectin domain family 9 member A), also known as DNGR-1, is a type II transmembrane glycoprotein member of the C-type lectin superfamily. Mature human CLEC9a consists of a 35aa cytoplasmic domain with an ITAM-like motif, a 21aa transmembrane segment, and a 185aa extracellular domain (ECD) that contains a stalk region and one C-type lectin domain (CTLD). Within the ECD, human CLEC9a shares 57% aa sequence identity with mouse and rat CLEC9a. Although the CTLD of CLEC9a structurally resembles that of other C-type lectins, it lacks the conserved residues that typically mediate calcium and carbohydrate binding. CLEC9a is expressed as a disulfide-linked homodimer of approximately 50kD N-glycosylated subunits. Human CLEC9a expression is restricted to a subpopulation of BDCA-3+ conventional dendritic cells (cDC) and CD16-monocytes. BDCA-3+ cDC are analagous to mouse CD8+ cDC which are specialized in antigenic cross-presentation in complex with MHC class I molecules. In mouse, CLEC9a is additionally expressed on plasmacytoid dendritic cells. CLEC9a ligation enhances antigen uptake and processing, leading to presentation on MHC class I and cytotoxic T cell (CTL) priming. In mouse, CLEC9a recognizes normally intracellular determinant(s) of necrotic cells and mediates their uptake by the dendritic cell. The subsequent antigenic cross-presentation to CTL is important for clearing necrotic cellular debris. CLEC9a signaling triggers activation of the tyrosine kinase Syk. Source: NS0-derived, murine myeloma cell line human CLEC9a (Lys57-Val241). SDS-PAGE: 55-65kD, reducing conditions Activity: Measured by flow cytometry for its ability to bind a ligand expressed in FasL-treated mouse B cells. At 100ng/ml, ≥50% of 7AAD positive cells bind to rhCLEC9a. Endotoxin Level: ≤1EU/1ug (LAL) Storage and Stability: Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile buffer or ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 6 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. | ||
Product Details
© 2020 Imugex All Rights Reserved